Now it hopes Afinitor will be its next cancer bestseller, says David Epstein, who leads Novartis' cancer drug business.

FORBES: Magazine Article

"Many of the solid tumors have very complex biology with redundant pathways, " says David Epstein, president of Novartis Oncology.

FORBES: Cancer Vaccine Finds A Proving Ground

But kidney cancer may be "the tip of the iceberg" for RAD001, says David Epstein, president of Novartis' cancer unit.

FORBES: Magazine Article

"The development of oncology products is not often a straight line, " says David Epstein , head of oncology at Novartis.

FORBES: Cancer Drugs On The Way, But Who Pays?

For uncommon cancers, "there are fewer therapies available and the route to market is clearer, " says Novartis cancer chief David Epstein.

FORBES: Magazine Article

The company started working on this potential Gleevec successor even before Gleevec was approved in 2001, says David Epstein, president of Novartis Oncology.

FORBES: The Race Is On

Mr. DAVID EPSTEIN (Reporter, Sports Illustrated): And in 2002, Major League Baseball and the players union agreed that the following year, they would have mandatory, random testing.

NPR: Report: A-Rod Tested Positive For Steroids

David Epstein, thanks for joining us.

NPR: Report: A-Rod Tested Positive For Steroids